

# VERTIGOPAS®

DIN-HM: 80024053

Oral Drops



## Composition:

100 g (= 103 ml) contains:

## Active ingredients:

Anamirta cocculus 4X	20 g
Conium maculatum 4X	20 g
Ambra grisea 6X	20 g
Oenanthe crocata 3X	20 g
Petroleum rectificatum 8X	20 g
Contains 23% vol. alcohol.	

## Non-medicinal ingredients:

Purified water, alcohol.

## Indication:

Homeopathic remedy for dizziness and vertigo.

## Dosage and administration:

Adults, children  $\geq 12$  years 10-30 drops 1-3 times/day, Children (ages 6-11) 5-15 drops 1-3 times/day, Children (ages 1-5) 5-10 drops 1-3 times/day, Infants (0-11 months) 1-5 drops 1-3 times/day. Acute dosing: Every 15-60 minutes (up to 12 times/day) or until improvement of symptoms. Then resume general dosing. The drops should be diluted in water.

## Comparison with VERTIGOHEEL:

Ingredient	VERTIGOHEEL	VERTIGOPAS
Anamirta cocculus	yes - D4	yes - 4X
Conium maculatum	yes - D3	yes - 4X
Ambra grisea	yes - D6	yes - 6X
Petroleum rectificatum	yes - D8	yes - 8X
Oenanthe crocata		yes - 3X



# VERTIGOPAS®

---

## Partial information on the therapeutically active constituents and their drug pictures according to the German Commission D:

Cocculus (indian cockle)	vertigo, motion sickness, nausea, cerebral vascular sclerosis
Conium (poison hemlock)	cerebral arteriosclerosis, depressive moods
Ambra grisea (ambergis)	dysregulation of the autonomic nervous system, arteriosclerosis
Oenanthe crocata	spasms, vertiginous attacks
Petroleum rectificatum	vertigo

### Contraindications/Cautions:

Consult a health care practitioner before using if pregnant or breastfeeding. Consult a healthcare practitioner before use in children less than 1 year of age.

### Side effects/Interactions:

None known.

### Research:

4,453 children were given VERTIGOPAS® for **dizziness** and its typical concomitant symptoms such as headache or nausea. Practitioners were asked to rate their experiences. Of the patients who had follow-up data, 97.6% of therapists surveyed rated the experience of using VERTIGOPAS® as positive.

84 patients were given VERTIGOPAS® to treat **vertigo** and its associated symptoms such as uncertainty in walking, rotary vertigo, staggering vertigo, tendency to fall, sweating, and nausea. An improvement was seen in most patients after only 1 week of treatment. At the end of 4 weeks, 90.6% of patients rated the efficacy of VERTIGOPAS® as good or very good.

**Disclaimer:** The above information was accumulated from a variety of sources including the German Commission D monograph and our Canadian and international practitioners. We require the practitioner to use his or her discretion to determine if the product is suitable to treat a particular health condition or patient. This information sheet is intended for professional use only. Any kind of reproduction and distribution must be approved by PASCOE Canada.